Purpose

Randomized controlled trial of an exposure-based behavioral treatment (CBT) in adults with functional dyspepsia who meet criteria for avoidant/restrictive food intake disorder (ARFID) with weight loss.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age at least 18 years at screening visit - Rome IV Functional Dyspepsia post-prandial distress type (with or without epigastric pain syndrome) - Negative upper endoscopy or upper radiographic GI series to rule out structural/organic cause for FD - Avoidant/Restrictive Food Intake Disorder (ARFID) diagnosis (by the Structured Clinical Interview for DSM-5; SCID-5 at Screening visit) - ≥5% weight loss from weight after functional dyspepsia symptom onset (at Screening visit) - Stable for outpatient care (based on the American Psychiatric Association Practice Guideline for the Treatment of Patients with Eating Disorders) - No previous history of CBT for functional dyspepsia or ARFID - Computer/internet webcam access - Fluency in English - Stable dose for 30 days if on any medication

Exclusion Criteria

  • Inability to provide informed consent - Presence of other conditions that could explain the patient's symptoms by chart: Pyloric or intestinal obstruction (by EGD, UGI, or Abdominal CT) Active H.pylori infection (by CLO test or stool antigen test) Active inflammatory bowel disease Eosinophilic gastroenteritis or eosinophilic esophagitis Acute renal failure Chronic renal failure (serum creatinine >3 mg/dL) and/or on hemodialysis or peritoneal dialysis Acute liver failure Any acute gastrointestinal process Any plausible structural or metabolic causes Heartburn as predominant symptom History of peptic ulcer - Symptom resolution with antisecretory therapy (PPI use for other reasons that did not resolve FD symptoms will be allowed) - History of gastrointestinal tract surgery (including gastrectomy, gastric bypass surgery, and small or large bowel resection) - History of any serious medical condition (e.g., cancer) - Use of narcotic analgesics greater than three days per week - Current pregnancy or breastfeeding within the last 8 weeks - Uncontrolled diabetes (indicated by HbA1c ≥7%) by chart - Intellectual disability by history - Current substance/alcohol use disorder within the past month - Current/history of psychosis (by Mini-International Neuropsychiatric Interview (MINI-Screen) - Current mania (by Mini-International Neuropsychiatric Interview (MINI-Screen) (defined as any manic episodes within the past 12 months) - Active suicidal ideation (by MINI-Screen) - Psychiatric disorder that would warrant independent attention (by Mini-International - Neuropsychiatric Interview (MINI-Screen)) - Current enteral or parenteral feeding - Plans to initiate another psychotherapy or pregnancy in the concurrent study period

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Other
Masking
Single (Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Cognitive Behavioral Therapy
Subjects will receive cognitive behavioral therapy for functional dyspepsia with avoidant restrictive food intake disorder.
  • Behavioral: Cognitive Behavioral Therapy
    Eight 1-hour sessions delivered weekly via the MGH-approved secure video platform Enterprise Zoom. Skills include: education about gut-brain regulation and weight loss, and regularizing eating to improve hunger and satiety cues; techniques to facilitate weight gain with targets of increased food volume and variety; and plan for maintenance of treatment gains.
No Intervention
Usual Care
In the usual care condition, participants will be allowed to continue with treatment they are already receiving at the time of randomization, and we will collect detailed data on the nature of these interventions. Participants will be allowed to pursue non study treatments in this condition.

Recruiting Locations

Massachusetts General Hospital
Boston, Massachusetts 02114
Contact:
Helen Burton Murray, PhD
617-643-7884
GIbehavioralresearch@mgh.harvard.edu

More Details

Status
Recruiting
Sponsor
Massachusetts General Hospital

Study Contact

Blythe Peterson, BS
617-643-7884
GIbehavioralresearch@mgh.harvard.edu

Detailed Description

The purpose of this study is to conduct a randomized controlled trial (RCT) of a cognitive-behavioral treatment (CBT) compared to usual care as the control with adults with functional dyspepsia who also meet criteria for avoidant/restrictive food intake disorder (ARFID). Participants randomized into the CBT group will receive eight 1-hour sessions delivered weekly via the MGH-approved secure video platform Enterprise Zoom while the usual care group will be allowed to continue with treatment they are already receiving at the time of randomization. Participants in the usual care group will be offered CBT after study participation. We will determine the feasibility and acceptability of the CBT and explore changes in clinical outcomes and preliminary mechanisms.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.